share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K：重大事件
美股SEC公告 ·  04/06 04:10

牛牛AI助理已提取核心訊息

On April 1, 2024, Timothy Stover, the Vice President, Corporate Controller, and the principal financial officer and principal accounting officer of NexImmune, Inc., announced his resignation effective April 16, 2024. The company clarified that Stover's departure was not due to any disagreements regarding operations, policies, or practices. Subsequently, on April 5, 2024, NexImmune's Board of Directors appointed Albert N. Marchio II as the Interim Chief Financial Officer. Marchio, with a 32-year tenure in the pharmaceutical industry, will assume the role of principal financial officer and principal accounting officer following Stover's departure. His previous experience includes roles at Danforth Advisors LLC, Fresh Tracks Therapeutics, Inc., and Edge Therapeutics, Inc., among others. The company has a Consulting Agreement with Danforth Advisors, which provides various services including the interim CFO services to be rendered by Marchio. The agreement also includes indemnification provisions and compensation on an hourly rate basis for services provided.
On April 1, 2024, Timothy Stover, the Vice President, Corporate Controller, and the principal financial officer and principal accounting officer of NexImmune, Inc., announced his resignation effective April 16, 2024. The company clarified that Stover's departure was not due to any disagreements regarding operations, policies, or practices. Subsequently, on April 5, 2024, NexImmune's Board of Directors appointed Albert N. Marchio II as the Interim Chief Financial Officer. Marchio, with a 32-year tenure in the pharmaceutical industry, will assume the role of principal financial officer and principal accounting officer following Stover's departure. His previous experience includes roles at Danforth Advisors LLC, Fresh Tracks Therapeutics, Inc., and Edge Therapeutics, Inc., among others. The company has a Consulting Agreement with Danforth Advisors, which provides various services including the interim CFO services to be rendered by Marchio. The agreement also includes indemnification provisions and compensation on an hourly rate basis for services provided.
2024年4月1日，NexImmune, Inc. 的副總裁、公司財務總監兼首席財務官兼首席會計官蒂莫西·斯托弗宣佈辭職，自2024年4月16日起生效。該公司澄清說，斯托弗的離職不是由於在運營、政策或做法方面存在任何分歧。隨後，NexImmune 董事會於 2024 年 4 月 5 日任命 Albert N. Marchio II 爲臨時首席財務官。在製藥行業工作了32年的馬爾基奧將在斯托弗離職後擔任首席財務官和首席會計官一職。他之前的經歷包括在丹佛斯顧問有限責任公司、Fresh Tracks Therapeutics, Inc.和Edge Therapeutics, Inc.等公司任職。該公司與Danforth Advisors簽訂了諮詢協議，後者提供各種服務，包括由Marchio提供的臨時首席財務官服務。該協議還包括賠償條款和按小時費率對所提供服務的補償。
2024年4月1日，NexImmune, Inc. 的副總裁、公司財務總監兼首席財務官兼首席會計官蒂莫西·斯托弗宣佈辭職，自2024年4月16日起生效。該公司澄清說，斯托弗的離職不是由於在運營、政策或做法方面存在任何分歧。隨後，NexImmune 董事會於 2024 年 4 月 5 日任命 Albert N. Marchio II 爲臨時首席財務官。在製藥行業工作了32年的馬爾基奧將在斯托弗離職後擔任首席財務官和首席會計官一職。他之前的經歷包括在丹佛斯顧問有限責任公司、Fresh Tracks Therapeutics, Inc.和Edge Therapeutics, Inc.等公司任職。該公司與Danforth Advisors簽訂了諮詢協議，後者提供各種服務，包括由Marchio提供的臨時首席財務官服務。該協議還包括賠償條款和按小時費率對所提供服務的補償。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間